Cargando…
Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients
Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal...
Autores principales: | , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122749/ https://www.ncbi.nlm.nih.gov/pubmed/33922368 http://dx.doi.org/10.3390/jcm10091830 |
_version_ | 1783692703657099264 |
---|---|
author | Jamroz-Wiśniewska, Anna Zajdel, Radosław Słowik, Agnieszka Marona, Monika Wnuk, Marcin Adamczyk-Sowa, Monika Adamczyk, Bożena Lasek-Bal, Anetta Puz, Przemysław Stęposz, Arkadiusz Krzystanek, Ewa Patalong-Ogiewa, Maja Pokryszko-Dragan, Anna Budrewicz, Sławomir Koziarska, Dorota Karbicka, Anna Wawrzyniak, Sławomir Fryze, Waldemar Furtak-Niczyporuk, Marzena Rejdak, Konrad |
author_facet | Jamroz-Wiśniewska, Anna Zajdel, Radosław Słowik, Agnieszka Marona, Monika Wnuk, Marcin Adamczyk-Sowa, Monika Adamczyk, Bożena Lasek-Bal, Anetta Puz, Przemysław Stęposz, Arkadiusz Krzystanek, Ewa Patalong-Ogiewa, Maja Pokryszko-Dragan, Anna Budrewicz, Sławomir Koziarska, Dorota Karbicka, Anna Wawrzyniak, Sławomir Fryze, Waldemar Furtak-Niczyporuk, Marzena Rejdak, Konrad |
author_sort | Jamroz-Wiśniewska, Anna |
collection | PubMed |
description | Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod. Methods: In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab (n = 135) or fingolimod (n = 201). Data on relapse rate, the expanded disability status scale, and MRI results were collected, and MRS was estimated. Results: NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod (p < 0.0001). Patients with MRS = 0 in the last year on platform therapy had the best NEDA-3 (71%) and patients with MRS = 3 had the worst NEDA-3 (41%) in the first year of treatment with the second-line therapy. Conclusion: We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy. |
format | Online Article Text |
id | pubmed-8122749 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81227492021-05-16 Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients Jamroz-Wiśniewska, Anna Zajdel, Radosław Słowik, Agnieszka Marona, Monika Wnuk, Marcin Adamczyk-Sowa, Monika Adamczyk, Bożena Lasek-Bal, Anetta Puz, Przemysław Stęposz, Arkadiusz Krzystanek, Ewa Patalong-Ogiewa, Maja Pokryszko-Dragan, Anna Budrewicz, Sławomir Koziarska, Dorota Karbicka, Anna Wawrzyniak, Sławomir Fryze, Waldemar Furtak-Niczyporuk, Marzena Rejdak, Konrad J Clin Med Brief Report Background: Reliable markers of disease outcomes in multiple sclerosis (MS) would help to predict the response to treatment in patients treated with high efficacy drugs. No evidence of disease activity (NEDA) has become a treatment goal whereas the modified Rio score (MRS) predicts future suboptimal responders to treatment. The aim of our study was to identify factors that would predict poor response to treatment with natalizumab and fingolimod. Methods: In the multicenter prospective trial, 336 subjects were enrolled, initiating therapy with natalizumab (n = 135) or fingolimod (n = 201). Data on relapse rate, the expanded disability status scale, and MRI results were collected, and MRS was estimated. Results: NEDA-3 after the first year of therapy was 73.9% for natalizumab and 54.8% for fingolimod (p < 0.0001). Patients with MRS = 0 in the last year on platform therapy had the best NEDA-3 (71%) and patients with MRS = 3 had the worst NEDA-3 (41%) in the first year of treatment with the second-line therapy. Conclusion: We conclude that switching to the second-line therapy should occur earlier to enable better results for patients treated with natalizumab or fingolimod. The outcome on both drugs is better with better neurological conditions and lower MRS of the patient on the platform therapy. MDPI 2021-04-22 /pmc/articles/PMC8122749/ /pubmed/33922368 http://dx.doi.org/10.3390/jcm10091830 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Jamroz-Wiśniewska, Anna Zajdel, Radosław Słowik, Agnieszka Marona, Monika Wnuk, Marcin Adamczyk-Sowa, Monika Adamczyk, Bożena Lasek-Bal, Anetta Puz, Przemysław Stęposz, Arkadiusz Krzystanek, Ewa Patalong-Ogiewa, Maja Pokryszko-Dragan, Anna Budrewicz, Sławomir Koziarska, Dorota Karbicka, Anna Wawrzyniak, Sławomir Fryze, Waldemar Furtak-Niczyporuk, Marzena Rejdak, Konrad Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients |
title | Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients |
title_full | Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients |
title_fullStr | Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients |
title_full_unstemmed | Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients |
title_short | Modified Rio Score with Platform Therapy Predicts Treatment Success with Fingolimod and Natalizumab in Relapsing-Remitting Multiple Sclerosis Patients |
title_sort | modified rio score with platform therapy predicts treatment success with fingolimod and natalizumab in relapsing-remitting multiple sclerosis patients |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8122749/ https://www.ncbi.nlm.nih.gov/pubmed/33922368 http://dx.doi.org/10.3390/jcm10091830 |
work_keys_str_mv | AT jamrozwisniewskaanna modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT zajdelradosław modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT słowikagnieszka modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT maronamonika modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT wnukmarcin modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT adamczyksowamonika modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT adamczykbozena modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT lasekbalanetta modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT puzprzemysław modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT steposzarkadiusz modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT krzystanekewa modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT patalongogiewamaja modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT pokryszkodragananna modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT budrewiczsławomir modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT koziarskadorota modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT karbickaanna modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT wawrzyniaksławomir modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT fryzewaldemar modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT furtakniczyporukmarzena modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients AT rejdakkonrad modifiedrioscorewithplatformtherapypredictstreatmentsuccesswithfingolimodandnatalizumabinrelapsingremittingmultiplesclerosispatients |